Carbimazole or methimazole in hyperthyroidism of pregnancy
Reading File
Finding Sources
Finding Sources
Searching PubMed
carbimazole methimazole hyperthyroidism pregnancy
Searching the Web
carbimazole vs methimazole pregnancy hyperthyroidism teratogenicity guidelines 2024 2025
Reading File
Reading File
Reading File
Searching PubMed
methimazole carbimazole embryopathy teratogenicity pregnancy
Reading File
Searching PubMed
antithyroid drugs pregnancy outcomes congenital anomalies
I have comprehensive data from multiple authoritative sources. Here is the synthesized answer:
Carbimazole vs. Methimazole in Hyperthyroidism of Pregnancy
Relationship Between the Two Drugs
Carbimazole is a prodrug of methimazole. It is rapidly converted to methimazole in vivo, with equivalent potency on a roughly 1:1 mg basis (some sources cite carbimazole 10 mg ≈ methimazole 6–8 mg active equivalent). Carbimazole is widely used in the UK, Europe, Australia, and Asia; methimazole is the form available in the US and elsewhere. Their teratogenic risk profile is identical because the active moiety is the same.
Both inhibit thyroid peroxidase (TPO), blocking iodine oxidation and organification, and both cross the placenta freely.
The Core Problem: Methimazole/Carbimazole Embryopathy
Exposure to MMI/carbimazole in the first trimester (period of organogenesis) is associated with a rare but recognized embryopathy, including:
| Defect | Notes |
|---|---|
| Aplasia cutis congenita | Scalp skin defects, most classic feature |
| Choanal atresia | Posterior nasal obstruction |
| Tracheo-oesophageal fistula / oesophageal atresia | |
| Abdominal wall defects (omphalocele) | |
| Eye anomalies | |
| Urinary tract abnormalities | |
| Circulatory defects |
Two meta-analyses have confirmed increased congenital anomaly risk with MMI/carbimazole; importantly, newer data (2023 meta-analysis, PMID 37205692) also show PTU carries congenital risks — no antithyroid drug is risk-free.
Trimester-Based Drug Strategy
First Trimester (weeks 1–14)
- Preferred drug: Propylthiouracil (PTU)
- PTU is preferred because MMI/carbimazole embryopathy risk is highest during organogenesis (weeks 6–10)
- PTU embryopathy risk is considered lower in T1 (though not zero — renal tract and face defects have been reported)
- If mild hyperthyroidism: consider avoiding ATDs altogether in T1 and monitoring closely
- If moderate-to-severe hyperthyroidism requiring treatment: PTU at the lowest effective dose
- β-blocker (labetalol preferred in pregnancy, not propranolol long-term) for symptomatic control, short-term only
"If available, propylthiouracil should be used until 14–16 weeks gestation because of the risk of rare cases of methimazole/carbimazole embryopathy, including aplasia cutis and other defects, such as choanal atresia and tracheoesophageal fistula." — Harrison's Principles of Internal Medicine, 22nd Edition
Second and Third Trimesters (weeks 14 onward)
- Switch to methimazole (or carbimazole)
- Reason: PTU carries a risk of severe maternal hepatotoxicity (including fulminant liver failure requiring transplant) — the FDA has restricted PTU use to T1 and thyroid storm
- MMI/carbimazole hepatotoxicity is milder (cholestatic pattern, rarely severe)
- Goal: maintain free T4 at or slightly above the upper limit of the trimester-specific reference range
- Typical maintenance: methimazole 2.5–10 mg/day or carbimazole equivalent
Why Free T4 (Not TSH) Is the Target
Fetal thyroid gland is more sensitive to transplacental antithyroid drug effect than the maternal gland. Over-treating the mother will suppress fetal thyroid more readily, risking fetal/neonatal hypothyroidism and goiter. TSH remains suppressed for months even after the mother is euthyroid, so it cannot guide dosing. Free T4 level at or just above normal is the correct titration target.
What NOT to Do
| Approach | Reason to Avoid |
|---|---|
| Block-and-replace regimen | Levothyroxine does not cross the placenta adequately; requires higher ATD doses → greater fetal hypothyroid risk |
| Radioiodine (¹³¹I) | Absolute contraindication — causes fetal hypothyroidism |
| Continuing MMI/carbimazole through T1 | Embryopathy risk |
| Continuing PTU beyond T1 | Maternal hepatotoxicity risk |
Monitoring During Pregnancy
- TRAb (TSH receptor antibodies): high levels can cause fetal/neonatal hyperthyroidism via placental transfer of stimulating immunoglobulins; monitor at ~22–26 weeks
- Fetal thyroid ultrasonography: monitor for goiter (indicates over-treatment or under-treatment)
- Neonatal thyroid function: assess at birth; neonatal hyperthyroidism has ~30% mortality if untreated
- Graves disease typically improves in T2/T3 (immune tolerance), allowing dose reduction or cessation; relapses postpartum
When to Consider Stopping ATDs in Pregnancy
Women who are euthyroid on low doses (methimazole ≤5–10 mg/day or PTU ≤100–200 mg/day) at the time of confirmed pregnancy, with favorable features (small goiter, low TRAb, prolonged remission), can be considered for ATD discontinuation under close monitoring. This avoids fetal exposure risk entirely.
Summary Table
| Parameter | PTU | MMI / Carbimazole |
|---|---|---|
| Trimester preferred | First (≤14 wk) | Second & Third |
| Teratogenicity | Lower T1 risk; renal/facial defects possible | Embryopathy (aplasia cutis, atresias) — mainly T1 |
| Hepatotoxicity | High risk (fulminant possible) | Low/cholestatic |
| T4→T3 conversion block | Yes | No |
| Placental transfer | Yes | Yes |
| Breast milk transfer | Low (compatible with breastfeeding) | Low (MMI ≤20 mg/day considered safe) |
Key sources: Harrison's Principles of Internal Medicine 22e; Goldman-Cecil Medicine; Tietz Textbook of Laboratory Medicine 7e; Katzung's Basic & Clinical Pharmacology 16e; Liu Y et al. PLoS One 2023 [PMID 37205692] — 2023 systematic review/meta-analysis confirming comparative safety data.
This is a shared conversation. Sign in to Orris to start your own chat.